skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Positron emission tomographic imaging of tumors using monoclonal antibodies. Progress report, November 1, 1992--October 31, 1993

Technical Report ·
DOI:https://doi.org/10.2172/10108717· OSTI ID:10108717

The overall goal of this project is to be able to combine the molecular specificity of monoclonal antibodies with the imaging advantages of positron emission tomography. During the past year, were have made progress in a number of areas. This report will focus on our studies evaluating the potential of two different methods for labeling a monoclonal antibody fragment with positron-emitting F-18 both in vitro and in athymic mice bearing subcutaneous D-54 MG human glioma xenografts. The F (a b{prime}){sub 2} fragment of Me1-14, a murine egg{sub 2a} reactive with an epitope of the tumor associated proteoglycan sulfate present in gliomas and melanomas, was used. This antibody is a particular interest because of our ongoing clinical radioimmunotherapy trails using Me1--14 that could ultimately benefit from the determination of quantitative dosimetry using monoclonal antibody PET imaging. Our results demonstrated, for the first time, that MAb fragments could be labeled with F-18 with retention of immunoreactivity and affinity. Further, they show that selective and specific tumor uptake of an F-18 labeled MAb fragment can be achieved in a xenograft model in a time frame compatible with the short half life of this nuclide.

Research Organization:
Duke Univ. Medical Center, Durham, NC (United States). Dept. of Radiology
Sponsoring Organization:
USDOE, Washington, DC (United States)
DOE Contract Number:
FG05-89ER60789
OSTI ID:
10108717
Report Number(s):
DOE/ER/60789-5; ON: DE94004419; BR: KP0601000
Resource Relation:
Other Information: PBD: 29 Jul 1993
Country of Publication:
United States
Language:
English